Article
Cardiac & Cardiovascular Systems
Elizabeth Joyce, Brian Haymart, Xiaowen Kong, Mona A. Ali, Mara Carrigan, Scott Kaatz, Vinay Shah, Eva Kline-Rogers, Jay Kozlowski, James B. Froehlich, Geoffrey D. Barnes
Summary: In patients with provoked venous thromboembolism (VTE), most individuals receive longer durations of anticoagulation compared to the recommended 3 months. This highlights the potential for improving care delivery and reducing the risk of anticoagulant-associated bleeding.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Medicine, General & Internal
Birgitte Tholin, Waleed Ghanima, Maria Lie Selle, Knut Stavem
Summary: This study found a lower incidence of venous thromboembolism (VTE) in both hospitalized and nonhospitalized patients with COVID-19 compared to previous reports, with higher rates in hospitalized patients. Age, previous history of VTE, and hospitalization were associated with the risk of VTE.
JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Rachael M. Cardinal, Frank D'Amico, Alyssa D'Addezio, Kaylee Dakers, Gregory Castelli
Summary: This study found that BMI was not associated with recurrence of VTE in extreme weight patients receiving DOAC therapy. However, significant differences in the proportions of major bleeding were observed among different BMI categories.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2021)
Article
Hematology
David Spirk, Tim Sebastian, Stefano Barco, Martin Banyai, Juerg H. Beer, Lucia Mazzolai, Thomas Baldi, Drahomir Aujesky, Daniel Hayoz, Rolf P. Engelberger, Thomas Kaeslin, Wolfgang Korte, Robert Escher, Marc Husmann, Marc Blondon, Nils Kucher
Summary: In patients with cancer-associated venous thromboembolism (VTE), the risk of recurrence is similar after incidental and symptomatic events. It is unknown whether the same applies to incidental VTE not associated with cancer. After comparing baseline characteristics, anticoagulation therapy, all-cause mortality, and VTE recurrence rates at 90 days between patients with incidental and symptomatic VTE, the study found that receiving anticoagulation therapy for at least 3 months was associated with lower mortality and recurrence rates in patients with incidental VTE regardless of cancer status. Additionally, among noncancer patients, early mortality and recurrence rates were similar after incidental versus symptomatic VTE.
THROMBOSIS AND HAEMOSTASIS
(2021)
Review
Cell Biology
Viktoria Muster, Thomas Gary
Summary: Glioblastoma patients have a high risk of developing venous thromboembolism, making therapeutic anticoagulation challenging with limited data available for this vulnerable patient group.
Review
Oncology
Lai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, Harinder Gill, Dennis Lee Sacdalan, Gwo Fuang Ho, Rajiv Parakh, Paresh Pai, Jen-Kuang Lee, Nannette Rey, Alexander T. Cohen
Summary: Direct oral anticoagulants (DOACs) have shown comparable efficacy and safety outcomes in Asian patients with cancer-associated thrombosis (CAT) compared to other races. Apixaban, edoxaban, or rivaroxaban can be considered as reasonable alternatives to low-molecular-weight heparin (LMWH) for anticoagulation in Asian patients with CAT.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Hematology
C. Heleen van Ommen, Klasien A. Bergman, Marit Boerma, Heleen A. Bouma, Albertine E. Donker, Melissa Gouvernante, Christian Hulzebos, Dalila Khandour, Ronny Knol, Marlou A. Raets, K. Djien Liem, Richard A. van Lingen, Moniek van de Loo, Enrico Lopriore, Mayke van der Putten, Jeanine J. Sol, Monique H. Suijker, Daniel C. Vijlbrief, Remco Visser, Mirjam M. van Weissenbruch
Summary: A national management guideline was developed in the Netherlands to create uniform management for catheter-related venous thromboembolism (CVTE) in critically ill (preterm) neonates. A prospective observational study of 115 infants showed that following the guideline led to a low incidence of recurrent venous thrombotic events and death due to CVTE, but major bleeding occurred in a small percentage of infants.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
(2023)
Review
Medicine, General & Internal
Xiaole Su, Bingjuan Yan, Lihua Wang, Hong Cheng, Yipu Chen
Summary: DOACs have similar efficacy as warfarin in the treatment of acute VTE, reducing recurrent VTE and VTE-related death, but are significantly superior to warfarin in reducing the risk of bleeding. There is no significant difference in the efficacy and safety of DOACs across different CrCl stratifications, but apixaban might be associated with a lower risk of bleeding in patients with VTE and CrCl >80 mL/min.
Article
Oncology
Gregory M. Gressel, Jenna Z. Marcus, Mary M. Mullen, Abdulrahman K. Sinno
Summary: This article discusses the use of DOAC in patients with gynecologic malignancies, providing clinical data and evidence quality, although studies were primarily conducted in mixed cancer subtype populations. Due to limited data on gynecologic cancer patients, the study results still provide the best evidence for current treatment recommendations.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Hematology
Alexander Cohen, Virginia Noxon, Amol Dhamane, Robert Bruette, Shrushti Shah, Dionne M. Hines, Tamuno Alfred, Xuemei Luo
Summary: This study compared the risks of recurrent venous thromboembolism (VTE), major bleeding (MB), and clinically relevant non-major bleeding (CRNMB) among cancer patients with brain cancer and other types of cancer who initiated apixaban, low molecular weight heparin (LMWH), or warfarin. The results showed that apixaban was associated with a lower risk of these adverse events compared to LMWH and warfarin, and there were no significant differences in the anticoagulant treatment effects between patients with brain cancer and those with other cancer.
THROMBOSIS RESEARCH
(2023)
Article
Medicine, General & Internal
Faizan Khan, Kednapa Thavorn, Doug Coyle, Sasha van Katwyk, Tobias Tritschler, Brian Hutton, Gregoire Le Gal, Marc Rodger, Dean Fergusson
Summary: This study aims to assess the differences in clinical benefits, harms, and costs of stopping versus continuing anticoagulant therapy indefinitely for a first unprovoked venous thromboembolism (VTE). A probabilistic Markov model will be developed to estimate life-years, quality-adjusted life-years, costs, and incremental cost-effectiveness ratios. The results will be disseminated through conferences and a peer-reviewed journal.
Review
Medicine, General & Internal
Ann-Rong Yan, Indira Samarawickrema, Mark Naunton, Gregory M. Peterson, Desmond Yip, Reza Mortazavi
Summary: This study aims to investigate the available VTE risk assessment tools for ambulatory patients with lung cancer and compare their predictive performance. Systematic evaluation and meta-analysis will be conducted to determine the incidence of VTE and the performance of the risk models included in the studies.
Article
Hematology
Anetta Undas
Summary: Fibrinolysis is crucial for maintaining or restoring the patency of veins and pulmonary arteries obstructed by thrombi. Impaired fibrinolysis is implicated in venous thromboembolism (VTE) through complex mechanisms, with markers like clot lysis time predicting recurrent deep-vein thrombosis and pulmonary embolism. This overview summarizes the link between fibrinolysis and VTE, along with its long-term consequences.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2021)
Review
Biochemistry & Molecular Biology
Mario Enrico Canonico, Ciro Santoro, Marisa Avvedimento, Giuseppe Giugliano, Giulia Elena Mandoli, Maria Prastaro, Anna Franzone, Raffaele Piccolo, Federica Ilardi, Matteo Cameli, Giovanni Esposito
Summary: Acute thrombotic events can reveal occult cancer in a significant number of cases. Malignancy interacts with the hemostatic system, leading to both thrombosis and bleeding. Cancer-related thrombotic events primarily affect the venous side and present in various conditions, including unusual sites of venous thrombosis. The selection of patients for anticoagulation management is complex, taking into account individual patient goals and preferences, prognosis of specific cancers, comorbidities, drug interactions, underweight states, and competing risks of morbidity and mortality. Anticoagulant treatment in cancer is widely debated, with direct oral anticoagulants showing efficacy and safety compared to traditional treatment.
Article
Hematology
Alberto Garcia-Ortega, Raquel Lopez-Reyes, Gabriel Anguera, Grace Oscullo, Agustina Rivas, Luciano Lopez-Jimenez, Alicia Lorenzo, Isabelle Mahe, Maurizio Ciammaichella, Manuel Monreal
Summary: Treatment of venous thromboembolism in solid organ transplant recipients is associated with an increased risk of bleeding compared to non-recipients, mainly influenced by liver transplant recipients. In non-liver solid organ transplant recipients, the risk of bleeding is similar to that in non-recipients.
THROMBOSIS RESEARCH
(2021)
Article
Rheumatology
Chandrasekar Gopalakrishnan, Rishi J. Desai, Jessica M. Franklin, Yinzhu Jin, Joyce Lii, Daniel H. Solomon, Jeffrey N. Katz, Yvonne C. Lee, Patricia D. Franklin, Seoyoung C. Kim
Summary: This study aimed to develop a claims-based model for predicting persistent high-dose opioid use among patients who underwent total knee replacement (TKR). The study utilized Medicare claims data and employed group-based trajectory modeling to identify different patterns of opioid use. The findings revealed that approximately 10.6% of older patients became persistent high-dose opioid users after TKR.
ARTHRITIS CARE & RESEARCH
(2022)
Article
Health Care Sciences & Services
Constance P. Fontanet, Niteesh K. Choudhry, Thomas Isaac, Thomas D. Sequist, Chandrasekar Gopalakrishnan, Joshua J. Gagne, Cynthia A. Jackevicius, Michael A. Fischer, Daniel H. Solomon, Julie C. Lauffenburger
Summary: Pharmacy fill data may serve as an effective alternative to insurer claims data for measuring medication adherence. Although pharmacy fill data predicted better disease control slightly more than claims-based data, the difference was not significant.
HEALTH SERVICES RESEARCH
(2022)
Article
Public, Environmental & Occupational Health
Richeek Pradhan, Elisabetta Patorno, Helen Tesfaye, Sebastian Schneeweiss, Hui Yin, Jessica Franklin, Ajinkya Pawar, Christina Santella, Oriana H. Y. Yu, Christel Renoux, Laurent Azoulay
Summary: The study compared GLP-1 receptor agonists users with different active comparator groups and found a modestly increased risk of anaphylactic reaction associated with GLP-1 RAs.
AMERICAN JOURNAL OF EPIDEMIOLOGY
(2022)
Letter
Medicine, General & Internal
Elisabetta Patorno, Phyo T. Htoo, Robert J. Glynn, Sebastian Schneeweiss, Deborah J. Wexler, Ajinkya Pawar, Lily G. Bessette, Kristyn Chin, BrendanM. Everett, Seoyoung C. Kim
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Elisabetta Patorno, Ajinkya Pawar, Deborah J. Wexler, Robert J. Glynn, Lily G. Bessette, Julie M. Paik, Mehdi Najafzadeh, Kimberly G. Brodovicz, Anouk Deruaz-Luyet, Sebastian Schneeweiss
Summary: This study found that compared to DPP-4 inhibitors, empagliflozin had a similar risk of MI/stroke but lower risk of HHF. Empagliflozin was associated with lower risk of all-cause mortality, a composite of MI/stroke/all-cause mortality, and had a safety profile consistent with documented information.
DIABETES OBESITY & METABOLISM
(2022)
Article
Clinical Neurology
Elisabetta Patorno, Sebastian Schneeweiss, Mary G. George, Xin Tong, Jessica M. Franklin, Ajinkya Pawar, Helen Mogun, Lidia M. V. R. Moura, Lee H. Schwamm
Summary: High-quality linkage between PCNASP and commercial claims data is feasible, revealing discrepancies between actual medication utilization and prescription fills for stroke patients, emphasizing the importance of longitudinal data for improving stroke patient care.
STROKE AND VASCULAR NEUROLOGY
(2022)
Meeting Abstract
Endocrinology & Metabolism
Alexander Kutz, Chandrasekar Gopalakrishnan, Dae H. Kim, Elisabetta Patorno
Article
Medicine, General & Internal
Ismaeel Yunusa, Joshua J. Gagne, Kazuki Yoshida, Katsiaryna Bykov
Summary: In this cohort study, patients treated with paroxetine or fluoxetine were found to have a slightly increased risk of opioid overdose when initiating oxycodone. This study highlights the importance of considering the potential drug-drug interactions when prescribing opioids.
Letter
Geriatrics & Gerontology
Victor Y. Liu, Ajinkya Pawar, Joel S. Weissman, Dae Hyun Kim
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2022)
Article
Clinical Neurology
Nazleen F. Khan, Katsiaryna Bykov, Michael Barnett, Robert Glynn, Seanna M. Vine, Joshua J. Gagne
Summary: This study compares the risk of opioid overdose among patients on long-term opioid therapy who concurrently initiate skeletal muscle relaxants. The study found that the use of baclofen, compared to cyclobenzaprine, was associated with opioid overdose, while the relationship between the use of other drugs and overdose risk was unclear.
Article
Medicine, General & Internal
Junyi Wang, Joshua J. Gagne, Sushama Kattinakere-Sreedhara, Michael A. Fischer, Katsiaryna Bykov
Summary: This study evaluated the association between the use of fluoroquinolones and hospital admission or emergency department visits for suicidal thoughts. The results showed that there was no significantly increased risk of suicidal thoughts associated with the use of fluoroquinolones compared to other antibiotics.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Meeting Abstract
Geriatrics & Gerontology
Chandrasekar Gopalakrishnan, Dae Kim, Elisabetta Patorno
INNOVATION IN AGING
(2022)
Meeting Abstract
Public, Environmental & Occupational Health
Alexander Kutz, Chandrasekar Gopalakrishnan, Dae Hyun Kim, Elisabetta Patorno
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2022)